Related Experiment Videos
Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk
1Cardiology Department, Auckland City Hospital, New Zealand. rstewart@adhb.govt.nz
Insights
The JUPITER trial demonstrated that rosuvastatin significantly reduced cardiovascular events in individuals with elevated C-reactive protein (CRP) and low LDL cholesterol. This highlights the role of inflammation reduction in statin therapy benefits.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Cardiovascular disease (CVD) remains a leading cause of mortality.
- Statins are widely used to lower LDL cholesterol, but their role in primary prevention for individuals without established CVD but with elevated inflammatory markers is debated.
- C-reactive protein (CRP) is a marker of inflammation associated with increased cardiovascular risk.
Purpose of the Study:
- To evaluate the efficacy of rosuvastatin in preventing vascular events in individuals with low LDL cholesterol but elevated CRP levels.
- To investigate the relationship between inflammation, LDL cholesterol reduction, and cardiovascular risk reduction.
Main Methods:
- The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) was a randomized, placebo-controlled trial.
- Nearly 18,000 participants with no history of CVD, average or low LDL cholesterol (<3.4 mmol/l), and high CRP (>2 mg/dl) were randomized to rosuvastatin 20 mg daily or placebo.
- The trial was terminated early due to significant observed benefits.
Main Results:
- Rosuvastatin significantly reduced the risk of major cardiovascular events by 46% compared to placebo.
- Participants achieving both low LDL cholesterol (<1.8 mmol/l) and low CRP (<2 mg/dl) on treatment experienced the greatest risk reduction.
- The findings suggest that statin benefits extend beyond LDL cholesterol lowering and are partly attributed to anti-inflammatory effects.
Conclusions:
- Rosuvastatin is effective in preventing vascular events in individuals with elevated CRP and low LDL cholesterol, suggesting a role for statins in primary prevention based on inflammatory markers.
- Reducing both LDL cholesterol and inflammation (CRP) is crucial for maximizing cardiovascular risk reduction.
- Statin treatment decisions should consider both lipid levels and inflammatory markers for optimal risk management.
Abstract:
Evaluation of: Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008). The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) randomized nearly 18,000 subjects with no history of cardiovascular disease and an average or low LDLcholesterol level (<3.4 mmol/l), but a high plasma level of C-reactive protein (CRP; >2 mg/dl), to rosuvastatin 20 mg or placebo daily. The trial was stopped early because of a highly statistically significant 46% reduction in cardiovascular events for patients randomized to rosuvastatin. Participants who achieved an LDL-cholesterol level lower than 1.8 mmol/l and a CRP level lower than 2 mg/dl on treatment had the greatest decrease in cardiovascular risk. The JUPITER trial provides evidence that the benefits of statins relate in part to decreased inflammation. Comparison with other statin trials indicates that absolute cardiovascular risk is an important predictor of benefit from statin treatment, and potent statins that result in a greater percentage reduction in LDLcholesterol and CRP are likely to reduce risk more. Targeting statin treatment based on LDL-cholesterol alone will not provide an optimal risk reduction for many individuals.
Related Concept Videos
01:26Atherosclerosis III: Management
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:30Coronary Artery Disease I: Introduction
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...